{"paper_id":"11daf21a-76d6-406c-adb5-6d7d8bf5c32f","body_text":"[ A23-117] Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V\nLast updated 01.03.2024\nProject no.:\nA23-117\nCommission:\nCommission awarded on 29.11.2023 by the Federal Joint Committee (G-BA).\nReport type:\nDossier assessment\nStatus:\nCommission completed\nDepartment/Division:\nDrug Assessment\nTopic:\nReproductive health and birth\nSymptomatic treatment of adult women of reproductive age with endometriosis who have a history of previous medical or surgical treatment\n- Women who are eligible for treatment with dienogest: added benefit not proven\n- Women who are not (or no longer) eligible for treatment with dienogest: added benefit not proven\nAfter completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.\nhttps://doi.org/10.60584/A23-117_en\n-\nExtract of dossier assessment: Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V\nDOI:\nhttps://doi.org/10.60584/A23-117_en\nEN, PDF, 345 kB, PDFpublished on Mar 1, 2024\n-\nDossier assessment: Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V\nDOI:\nhttps://dx.doi.org/10.60584/A23-117\nDE, PDF, 902 kB, PDFpublished on Mar 1, 2024\n| Project no. | Title | Status |\n|---|---|---|\n| A21-112 | Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V | Commission completed |","source_license":"CC0","license_restricted":false}